Health Policy and Practice

Cost-effectiveness of Hepatic Arterial Chemoembolization for Colorectal Liver Metastases Refractory to Systemic Chemotherapy

Abstract

PURPOSE: To calculate the cost-effectiveness of hepatic arterial chemoembolization (HACE) for the treatment of colorectal liver metastases (CLM) over a range of survival benefits and to determine the survival benefit that HACE must confer to meet three thresholds of cost-effectiveness.

MATERIALS AND METHODS: A spreadsheet model was used to estimate the marginal direct cost of HACE compared with palliative care from a payer’s perspective. Medicare reimbursement amounts represented costs, while probabilities of reembolization and complications were obtained from records of patients who underwent HACE. Marginal cost-effectiveness was calculated from marginal direct cost by varying the survival benefit of HACE compared with palliative care from 0 to 24 months. Break-even analyses were conducted to determine the survival benefit at which the cost-effectiveness of HACE would decrease below three threshold values derived from a literature review.

RESULTS: The marginal cost-effectiveness of HACE compared with palliative care, given survival benefits of 3, 6, and 12 months, was $82,385, $41,193, and $21,045 per life-year (LY) gained, respectively. Cost-effectiveness thresholds of $20,000 (strict), $50,000 (moderate), and $100,000 (generous) per LY gained required survival benefits of 12.63, 4.94, and 2.47 months, respectively, more than the expected baseline.

CONCLUSION: The cost-effectiveness of HACE for the treatment of CLM varies considerably according to the anticipated survival benefit. Results of future randomized controlled trials must demonstrate a survival benefit of nearly 5 months for HACE to meet the moderate cost-effectiveness standard of $50,000 per LY gained.

References

1 Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397-401. Link, Google Scholar
2 Sakurai M, Okamura J, Kuroda C. Transcatheter chemo-embolization effective for treating hepatocellular carcinoma: a histopathologic study. Cancer 1984; 54:387-392. Crossref, Medline, Google Scholar
3 Venook AP, Stagg RJ, Lewis BJ, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8:1108-1114. Crossref, Medline, Google Scholar
4 Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11:181-184. Crossref, Medline, Google Scholar
5 Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992; 163:387-394. Crossref, Medline, Google Scholar
6 Stuart K, Stokes K, Jenkins R, Trey C, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder combination. Cancer 1993; 72:3202-3209. Crossref, Medline, Google Scholar
7 Kanematsu T, Matsumata T, Shirabe K, et al. A comparative study of hepatic resection and transcatheter arterial embolization for the treatment of primary hepatocellular carcinoma. Cancer 1993; 71:2181-2186. Crossref, Medline, Google Scholar
8 Madden MV, Krige JEJ, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34:1598-1600. Crossref, Medline, Google Scholar
9 Group d’Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261. Crossref, Medline, Google Scholar
10 Solomon B, Soulen MC, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10:793-798. Crossref, Medline, Google Scholar
11 Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 1992; 163:479-483. Crossref, Medline, Google Scholar
12 Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993; 189:541-547. Link, Google Scholar
13 Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer 1993; 71:2624-2630. Crossref, Medline, Google Scholar
14 Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175:408-412. Crossref, Medline, Google Scholar
15 Taniguchi H, Takahashi T, Yamaguchi T, Sawai K. Intraarterial infusion chemotherapy for metastatic liver tumors using multiple anti-cancer agents suspended in a lipid contrast medium. Cancer 1989; 64:2001-2006. Crossref, Medline, Google Scholar
16 Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189:417-422. Link, Google Scholar
17 Kameyama M, Imaoka S, Fukuda I, et al. Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastasis of colorectal cancer. Surgery 1993; 114:97-101. Medline, Google Scholar
18 Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74:1706-1712. Crossref, Medline, Google Scholar
19 Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 1997; 40:770-775. Crossref, Medline, Google Scholar
20 Tellez C, Benson AB, III, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82:1250-1259. Crossref, Medline, Google Scholar
21 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30:969-985. Medline, Google Scholar
22 Miller DL. First, do no harm. Radiology 1996; 198:10-12. Link, Google Scholar
23 Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343:1405-1410. Crossref, Medline, Google Scholar
24 National Heritage Insurance Company. Medicare B bulletin. Health Care Financing Administration Web site. ; Available at: http://www.hcfa.gov. Accessed March 1999.. Google Scholar
REF25 1998 Drug Topics Red Book Montvale, NJ: Medical Economics, 1998. Google Scholar
26 Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85:1460-1474. Crossref, Medline, Google Scholar
27 Smith TJ, Hillner BE. Decision analysis: a practical example. Oncology (Huntingt) 1995; 9(suppl 11):37-45. Medline, Google Scholar
28 Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146:473-481. Medline, Google Scholar
29 Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 1995; 60:116-121. Crossref, Medline, Google Scholar
30 Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198:33-40. Link, Google Scholar
31 Burke D, Allen-Mersh TG. Colorectal liver metastases. Postgrad Med J 1996; 72:464-469. Crossref, Medline, Google Scholar
32 Borner M, Castiglione M, Triller J, et al. Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Ann Oncol 1992; 3:113-115. Crossref, Medline, Google Scholar
33 Neuman ML, Murphy BD, Rosen MP. Bedside placement of peripherally inserted central catheters: a cost-effectiveness analysis. Radiology 1998; 206:423-428. Link, Google Scholar
34 Picus D. Comparing competing medical procedures: costs or charges—what should it matter?. Radiology 1996; 199:623-625. Link, Google Scholar
35 Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analysis in the medical literature: are the methods being used correctly?. Ann Intern Med 1992; 116:238-244. Crossref, Medline, Google Scholar
36 Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993; 306:570-572. Crossref, Medline, Google Scholar
37 Blendon RJ, Brodie M, Hyams TS, Benson JM. The American public and the critical choices for health system reform. JAMA 1994; 271:1539-1544. Crossref, Medline, Google Scholar

Article History

Published in print: Aug 2000

Vol. 216, No. 2

Metrics

Downloaded 521 times

Altmetric Score